Driven by science and powered by innovation, Helixial is committed to unwinding the genetic
blueprint of disease to bring clarity to healthcare decisions. Whether it’s identifying elusive
infections or detecting cancer at the molecular level, our solutions are built to empower
clinicians, laboratories, and researchers with data they can trust for better patient care.
Equipped with cutting-edge technology and highly trained scientists and medical researchers, we are
on a mission to make next-generation, precision healthcare more accessible to the people of India.
Next-Generation Sequencing (NGS) is an advanced technology for high-throughput DNA and RNA sequencing, enabling rapid and parallel analysis of entire genomes or targeted regions. By integrating innovative sequencing chemistries, diverse platforms, and powerful bioinformatics, NGS offers a faster, more scalable alternative to traditional Sanger sequencing.
Incorporating AI, next-gen sequencing, and big data, we offer swift, highly precise, and personalized diagnoses of infectious diseases, including non-culturable strains with their resistance to antibiotics, and cancer detection.
Unwinding genomic data for next-generation diagnostics
CancerFind™ is a revolutionary blood-based test for Multi-Cancer Early Detection (MCED). To identify the presence of various cancer types through a single, non-invasive blood draw.
CancerDetect™: Personalized Liquid Biopsy for early detection of cancer recurrence. With CancerDetect™, we bring next-generation cancer surveillance to the forefront—empowering proactive, personalized, and data-driven oncology care.
AlphaLiquid®100 is an innovative, cutting-edge liquid biopsy test that empowers personalized cancer care by detecting biomarkers across 118 cancer-related genes through just one blood draw.
This non-invasive, highly advanced test is essential for predicting a patient's response or resistance to targeted therapies.
